APO Research
Talk to an analyst

APO RESEARCH · REPORT

Varicella Virus Attenuated Live Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Varicella Virus Attenuated Live Vaccine Market Analysis and Forecast 2026-2032

22 December 2025192 pages

Choose your research edition.

Industry ResearchVaricella Virus Attenuated Live Vaccine Industry Research Report 2026118 pages · $2,950 USDIndustry Growth & TrendsGlobal Varicella Virus Attenuated Live Vaccine Industry Growth and Trends Forecast to 203295 pages · $3,450 USDMarket StructureGlobal Varicella Virus Attenuated Live Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032187 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Varicella Virus Attenuated Live Vaccine Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Varicella Virus Attenuated Live Vaccine Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Varicella Virus Attenuated Live Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Varicella Virus Attenuated Live Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Varicella Virus Attenuated Live Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Varicella Virus Attenuated Live Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Varicella Virus Attenuated Live Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Varicella Virus Attenuated Live Vaccine include GSK, Changsheng, Sanofi, Merck, Biken, Shanghai Institute, Keygen, Green Cross and BCHT, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Varicella Virus Attenuated Live Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Varicella Virus Attenuated Live Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Varicella Virus Attenuated Live Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Varicella Virus Attenuated Live Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Varicella Virus Attenuated Live Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Varicella Virus Attenuated Live Vaccine sales, projected growth trends, production technology, application and end-user industry.

Varicella Virus Attenuated Live Vaccine Segment by Company

GSK

Changsheng

Sanofi

Merck

Biken

Shanghai Institute

Keygen

Green Cross

BCHT

Varicella Virus Attenuated Live Vaccine Segment by Type

Child

Adult

Varicella Virus Attenuated Live Vaccine Segment by Application

Government Institution

Private Sector

Other

Varicella Virus Attenuated Live Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Varicella Virus Attenuated Live Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Varicella Virus Attenuated Live Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Varicella Virus Attenuated Live Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Varicella Virus Attenuated Live Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Varicella Virus Attenuated Live Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Varicella Virus Attenuated Live Vaccine sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Varicella Virus Attenuated Live Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Child Major Manufacturers Table 3. Adult Major Manufacturers Table 4. Global Varicella Virus Attenuated Live Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Government Institution Major Manufacturers Table 6. Private Sector Major Manufacturers Table 7. Other Major Manufacturers Table 8. Varicella Virus Attenuated Live Vaccine Industry Trends Table 9. Varicella Virus Attenuated Live Vaccine Industry Drivers Table 10. Varicella Virus Attenuated Live Vaccine Industry Opportunities and Challenges Table 11. Varicella Virus Attenuated Live Vaccine Industry Restraints Table 12. Global Varicella Virus Attenuated Live Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 13. Global Varicella Virus Attenuated Live Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 14. Global Varicella Virus Attenuated Live Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 15. Global Varicella Virus Attenuated Live Vaccine Revenue Market Share by Region (2021-2026) Table 16. Global Varicella Virus Attenuated Live Vaccine Revenue Market Share by Region (2027-2032) Table 17. Global Varicella Virus Attenuated Live Vaccine Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 18. Global Varicella Virus Attenuated Live Vaccine Sales by Region (2021-2026) & (k units) Table 19. Global Varicella Virus Attenuated Live Vaccine Sales by Region (2027-2032) & (k units) Table 20. Global Varicella Virus Attenuated Live Vaccine Sales Market Share by Region (2021-2026) Table 21. Global Varicella Virus Attenuated Live Vaccine Sales Market Share by Region (2027-2032) Table 22. Global Varicella Virus Attenuated Live Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 23. Global Varicella Virus Attenuated Live Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 24. Global Varicella Virus Attenuated Live Vaccine Sales by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Varicella Virus Attenuated Live Vaccine Sales Market Share by Manufacturers (2021-2026) Table 26. Global Varicella Virus Attenuated Live Vaccine Sales Price (US$/unit) of Manufacturers (2021-2026) Table 27. Global Varicella Virus Attenuated Live Vaccine Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 28. Global Varicella Virus Attenuated Live Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 29. Global Varicella Virus Attenuated Live Vaccine Manufacturers, Product Type & Application Table 30. Global Varicella Virus Attenuated Live Vaccine Manufacturers' Establishment Date Table 31. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 32. Global Varicella Virus Attenuated Live Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 33. Global Varicella Virus Attenuated Live Vaccine Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Varicella Virus Attenuated Live Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 35. Global Varicella Virus Attenuated Live Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 36. Global Varicella Virus Attenuated Live Vaccine Revenue Market Share by Type (2021-2026) Table 37. Global Varicella Virus Attenuated Live Vaccine Revenue Market Share by Type (2027-2032) Table 38. Global Varicella Virus Attenuated Live Vaccine Sales by Type 2021 VS 2025 VS 2032 (k units) Table 39. Global Varicella Virus Attenuated Live Vaccine Sales by Type (2021-2026) & (k units) Table 40. Global Varicella Virus Attenuated Live Vaccine Sales by Type (2027-2032) & (k units) Table 41. Global Varicella Virus Attenuated Live Vaccine Sales Market Share by Type (2021-2026) Table 42. Global Varicella Virus Attenuated Live Vaccine Sales Market Share by Type (2027-2032) Table 43. Global Varicella Virus Attenuated Live Vaccine Price by Type (2021-2026) & (US$/unit) Table 44. Global Varicella Virus Attenuated Live Vaccine Price by Type (2027-2032) & (US$/unit) Table 45. Global Varicella Virus Attenuated Live Vaccine Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 46. Global Varicella Virus Attenuated Live Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 47. Global Varicella Virus Attenuated Live Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 48. Global Varicella Virus Attenuated Live Vaccine Revenue Market Share by Application (2021-2026) Table 49. Global Varicella Virus Attenuated Live Vaccine Revenue Market Share by Application (2027-2032) Table 50. Global Varicella Virus Attenuated Live Vaccine Sales by Application 2021 VS 2025 VS 2032 (k units) Table 51. Global Varicella Virus Attenuated Live Vaccine Sales by Application (2021-2026) & (k units) Table 52. Global Varicella Virus Attenuated Live Vaccine Sales by Application (2027-2032) & (k units) Table 53. Global Varicella Virus Attenuated Live Vaccine Sales Market Share by Application (2021-2026) Table 54. Global Varicella Virus Attenuated Live Vaccine Sales Market Share by Application (2027-2032) Table 55. Global Varicella Virus Attenuated Live Vaccine Price by Application (2021-2026) & (US$/unit) Table 56. Global Varicella Virus Attenuated Live Vaccine Price by Application (2027-2032) & (US$/unit) Table 57. GSK Company Information Table 58. GSK Business Overview Table 59. GSK Varicella Virus Attenuated Live Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 60. GSK Varicella Virus Attenuated Live Vaccine Product Portfolio Table 61. GSK Recent Development Table 62. Changsheng Company Information Table 63. Changsheng Business Overview Table 64. Changsheng Varicella Virus Attenuated Live Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 65. Changsheng Varicella Virus Attenuated Live Vaccine Product Portfolio Table 66. Changsheng Recent Development Table 67. Sanofi Company Information Table 68. Sanofi Business Overview Table 69. Sanofi Varicella Virus Attenuated Live Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 70. Sanofi Varicella Virus Attenuated Live Vaccine Product Portfolio Table 71. Sanofi Recent Development Table 72. Merck Company Information Table 73. Merck Business Overview Table 74. Merck Varicella Virus Attenuated Live Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 75. Merck Varicella Virus Attenuated Live Vaccine Product Portfolio Table 76. Merck Recent Development Table 77. Biken Company Information Table 78. Biken Business Overview Table 79. Biken Varicella Virus Attenuated Live Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 80. Biken Varicella Virus Attenuated Live Vaccine Product Portfolio Table 81. Biken Recent Development Table 82. Shanghai Institute Company Information Table 83. Shanghai Institute Business Overview Table 84. Shanghai Institute Varicella Virus Attenuated Live Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 85. Shanghai Institute Varicella Virus Attenuated Live Vaccine Product Portfolio Table 86. Shanghai Institute Recent Development Table 87. Keygen Company Information Table 88. Keygen Business Overview Table 89. Keygen Varicella Virus Attenuated Live Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 90. Keygen Varicella Virus Attenuated Live Vaccine Product Portfolio Table 91. Keygen Recent Development Table 92. Green Cross Company Information Table 93. Green Cross Business Overview Table 94. Green Cross Varicella Virus Attenuated Live Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 95. Green Cross Varicella Virus Attenuated Live Vaccine Product Portfolio Table 96. Green Cross Recent Development Table 97. BCHT Company Information Table 98. BCHT Business Overview Table 99. BCHT Varicella Virus Attenuated Live Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 100. BCHT Varicella Virus Attenuated Live Vaccine Product Portfolio Table 101. BCHT Recent Development Table 102. North America Varicella Virus Attenuated Live Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 103. North America Varicella Virus Attenuated Live Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 104. North America Varicella Virus Attenuated Live Vaccine Sales by Type (2021-2026) & (k units) Table 105. North America Varicella Virus Attenuated Live Vaccine Sales by Type (2027-2032) & (k units) Table 106. North America Varicella Virus Attenuated Live Vaccine Sales Price by Type (2021-2026) & (US$/unit) Table 107. North America Varicella Virus Attenuated Live Vaccine Sales Price by Type (2027-2032) & (US$/unit) Table 108. North America Varicella Virus Attenuated Live Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 109. North America Varicella Virus Attenuated Live Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 110. North America Varicella Virus Attenuated Live Vaccine Sales by Application (2021-2026) & (k units) Table 111. North America Varicella Virus Attenuated Live Vaccine Sales by Application (2027-2032) & (k units) Table 112. North America Varicella Virus Attenuated Live Vaccine Sales Price by Application (2021-2026) & (US$/unit) Table 113. North America Varicella Virus Attenuated Live Vaccine Sales Price by Application (2027-2032) & (US$/unit) Table 114. North America Varicella Virus Attenuated Live Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 115. North America Varicella Virus Attenuated Live Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 116. North America Varicella Virus Attenuated Live Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 117. North America Varicella Virus Attenuated Live Vaccine Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 118. North America Varicella Virus Attenuated Live Vaccine Sales by Country (2021-2026) & (k units) Table 119. North America Varicella Virus Attenuated Live Vaccine Sales by Country (2027-2032) & (k units) Table 120. North America Varicella Virus Attenuated Live Vaccine Sales Price by Country (2021-2026) & (US$/unit) Table 121. North America Varicella Virus Attenuated Live Vaccine Sales Price by Country (2027-2032) & (US$/unit) Table 122. United States Varicella Virus Attenuated Live Vaccine Revenue (2021-2032) & (US$ Million) Table 123. Canada Varicella Virus Attenuated Live Vaccine Revenue (2021-2032) & (US$ Million) Table 124. Mexico Varicella Virus Attenuated Live Vaccine Revenue (2021-2032) & (US$ Million) Table 125. Europe Varicella Virus Attenuated Live Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 126. Europe Varicella Virus Attenuated Live Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 127. Europe Varicella Virus Attenuated Live Vaccine Sales by Type (2021-2026) & (k units) Table 128. Europe Varicella Virus Attenuated Live Vaccine Sales by Type (2027-2032) & (k units) Table 129. Europe Varicella Virus Attenuated Live Vaccine Sales Price by Type (2021-2026) & (US$/unit) Table 130. Europe Varicella Virus Attenuated Live Vaccine Sales Price by Type (2027-2032) & (US$/unit) Table 131. Europe Varicella Virus Attenuated Live Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 132. Europe Varicella Virus Attenuated Live Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 133. Europe Varicella Virus Attenuated Live Vaccine Sales by Application (2021-2026) & (k units) Table 134. Europe Varicella Virus Attenuated Live Vaccine Sales by Application (2027-2032) & (k units) Table 135. Europe Varicella Virus Attenuated Live Vaccine Sales Price by Application (2021-2026) & (US$/unit) Table 136. Europe Varicella Virus Attenuated Live Vaccine Sales Price by Application (2027-2032) & (US$/unit) Table 137. Europe Varicella Virus Attenuated Live Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 138. Europe Varicella Virus Attenuated Live Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 139. Europe Varicella Virus Attenuated Live Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 140. Europe Varicella Virus Attenuated Live Vaccine Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 141. Europe Varicella Virus Attenuated Live Vaccine Sales by Country (2021-2026) & (k units) Table 142. Europe Varicella Virus Attenuated Live Vaccine Sales by Country (2027-2032) & (k units) Table 143. Europe Varicella Virus Attenuated Live Vaccine Sales Price by Country (2021-2026) & (US$/unit) Table 144. Europe Varicella Virus Attenuated Live Vaccine Sales Price by Country (2027-2032) & (US$/unit) Table 145. Germany Varicella Virus Attenuated Live Vaccine Revenue (2021-2032) & (US$ Million) Table 146. France Varicella Virus Attenuated Live Vaccine Revenue (2021-2032) & (US$ Million) Table 147. U.K. Varicella Virus Attenuated Live Vaccine Revenue (2021-2032) & (US$ Million) Table 148. Italy Varicella Virus Attenuated Live Vaccine Revenue (2021-2032) & (US$ Million) Table 149. Russia Varicella Virus Attenuated Live Vaccine Revenue (2021-2032) & (US$ Million) Table 150. Spain Varicella Virus Attenuated Live Vaccine Revenue (2021-2032) & (US$ Million) Table 151. Netherlands Varicella Virus Attenuated Live Vaccine Revenue (2021-2032) & (US$ Million) Table 152. Switzerland Varicella Virus Attenuated Live Vaccine Revenue (2021-2032) & (US$ Million) Table 153. Sweden Varicella Virus Attenuated Live Vaccine Revenue (2021-2032) & (US$ Million) Table 154. Poland Varicella Virus Attenuated Live Vaccine Revenue (2021-2032) & (US$ Million) Table 155. China Varicella Virus Attenuated Live Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 156. China Varicella Virus Attenuated Live Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 157. China Varicella Virus Attenuated Live Vaccine Sales by Type (2021-2026) & (k units) Table 158. China Varicella Virus Attenuated Live Vaccine Sales by Type (2027-2032) & (k units) Table 159. China Varicella Virus Attenuated Live Vaccine Sales Price by Type (2021-2026) & (US$/unit) Table 160. China Varicella Virus Attenuated Live Vaccine Sales Price by Type (2027-2032) & (US$/unit) Table 161. China Varicella Virus Attenuated Live Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 162. China Varicella Virus Attenuated Live Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 163. China Varicella Virus Attenuated Live Vaccine Sales by Application (2021-2026) & (k units) Table 164. China Varicella Virus Attenuated Live Vaccine Sales by Application (2027-2032) & (k units) Table 165. China Varicella Virus Attenuated Live Vaccine Sales Price by Application (2021-2026) & (US$/unit) Table 166. China Varicella Virus Attenuated Live Vaccine Sales Price by Application (2027-2032) & (US$/unit) Table 167. Asia Varicella Virus Attenuated Live Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 168. Asia Varicella Virus Attenuated Live Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 169. Asia Varicella Virus Attenuated Live Vaccine Sales by Type (2021-2026) & (k units) Table 170. Asia Varicella Virus Attenuated Live Vaccine Sales by Type (2027-2032) & (k units) Table 171. Asia Varicella Virus Attenuated Live Vaccine Sales Price by Type (2021-2026) & (US$/unit) Table 172. Asia Varicella Virus Attenuated Live Vaccine Sales Price by Type (2027-2032) & (US$/unit) Table 173. Asia Varicella Virus Attenuated Live Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 174. Asia Varicella Virus Attenuated Live Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 175. Asia Varicella Virus Attenuated Live Vaccine Sales by Application (2021-2026) & (k units) Table 176. Asia Varicella Virus Attenuated Live Vaccine Sales by Application (2027-2032) & (k units) Table 177. Asia Varicella Virus Attenuated Live Vaccine Sales Price by Application (2021-2026) & (US$/unit) Table 178. Asia Varicella Virus Attenuated Live Vaccine Sales Price by Application (2027-2032) & (US$/unit) Table 179. Asia Varicella Virus Attenuated Live Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 180. Asia Varicella Virus Attenuated Live Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 181. Asia Varicella Virus Attenuated Live Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 182. Asia Varicella Virus Attenuated Live Vaccine Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 183. Asia Varicella Virus Attenuated Live Vaccine Sales by Country (2021-2026) & (k units) Table 184. Asia Varicella Virus Attenuated Live Vaccine Sales by Country (2027-2032) & (k units) Table 185. Asia Varicella Virus Attenuated Live Vaccine Sales Price by Country (2021-2026) & (US$/unit) Table 186. Asia Varicella Virus Attenuated Live Vaccine Sales Price by Country (2027-2032) & (US$/unit) Table 187. Japan Varicella Virus Attenuated Live Vaccine Revenue (2021-2032) & (US$ Million) Table 188. South Korea Varicella Virus Attenuated Live Vaccine Revenue (2021-2032) & (US$ Million) Table 189. India Varicella Virus Attenuated Live Vaccine Revenue (2021-2032) & (US$ Million) Table 190. Australia Varicella Virus Attenuated Live Vaccine Revenue (2021-2032) & (US$ Million) Table 191. Taiwan Varicella Virus Attenuated Live Vaccine Revenue (2021-2032) & (US$ Million) Table 192. Southeast Asia Varicella Virus Attenuated Live Vaccine Revenue (2021-2032) & (US$ Million) Table 193. SAMEA Varicella Virus Attenuated Live Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 194. SAMEA Varicella Virus Attenuated Live Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 195. SAMEA Varicella Virus Attenuated Live Vaccine Sales by Type (2021-2026) & (k units) Table 196. SAMEA Varicella Virus Attenuated Live Vaccine Sales by Type (2027-2032) & (k units) Table 197. SAMEA Varicella Virus Attenuated Live Vaccine Sales Price by Type (2021-2026) & (US$/unit) Table 198. SAMEA Varicella Virus Attenuated Live Vaccine Sales Price by Type (2027-2032) & (US$/unit) Table 199. SAMEA Varicella Virus Attenuated Live Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 200. SAMEA Varicella Virus Attenuated Live Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 201. SAMEA Varicella Virus Attenuated Live Vaccine Sales by Application (2021-2026) & (k units) Table 202. SAMEA Varicella Virus Attenuated Live Vaccine Sales by Application (2027-2032) & (k units) Table 203. SAMEA Varicella Virus Attenuated Live Vaccine Sales Price by Application (2021-2026) & (US$/unit) Table 204. SAMEA Varicella Virus Attenuated Live Vaccine Sales Price by Application (2027-2032) & (US$/unit) Table 205. SAMEA Varicella Virus Attenuated Live Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 206. SAMEA Varicella Virus Attenuated Live Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 207. SAMEA Varicella Virus Attenuated Live Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 208. SAMEA Varicella Virus Attenuated Live Vaccine Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 209. SAMEA Varicella Virus Attenuated Live Vaccine Sales by Country (2021-2026) & (k units) Table 210. SAMEA Varicella Virus Attenuated Live Vaccine Sales by Country (2027-2032) & (k units) Table 211. SAMEA Varicella Virus Attenuated Live Vaccine Sales Price by Country (2021-2026) & (US$/unit) Table 212. SAMEA Varicella Virus Attenuated Live Vaccine Sales Price by Country (2027-2032) & (US$/unit) Table 213. Brazil Varicella Virus Attenuated Live Vaccine Revenue (2021-2032) & (US$ Million) Table 214. Argentina Varicella Virus Attenuated Live Vaccine Revenue (2021-2032) & (US$ Million) Table 215. Chile Varicella Virus Attenuated Live Vaccine Revenue (2021-2032) & (US$ Million) Table 216. Colombia Varicella Virus Attenuated Live Vaccine Revenue (2021-2032) & (US$ Million) Table 217. Peru Varicella Virus Attenuated Live Vaccine Revenue (2021-2032) & (US$ Million) Table 218. Saudi Arabia Varicella Virus Attenuated Live Vaccine Revenue (2021-2032) & (US$ Million) Table 219. Israel Varicella Virus Attenuated Live Vaccine Revenue (2021-2032) & (US$ Million) Table 220. UAE Varicella Virus Attenuated Live Vaccine Revenue (2021-2032) & (US$ Million) Table 221. Turkey Varicella Virus Attenuated Live Vaccine Revenue (2021-2032) & (US$ Million) Table 222. Iran Varicella Virus Attenuated Live Vaccine Revenue (2021-2032) & (US$ Million) Table 223. Egypt Varicella Virus Attenuated Live Vaccine Revenue (2021-2032) & (US$ Million) Table 224. Key Raw Materials Table 225. Raw Materials Key Suppliers Table 226. Varicella Virus Attenuated Live Vaccine Distributors List Table 227. Varicella Virus Attenuated Live Vaccine Customers List Table 228. Research Programs/Design for This Report Table 229. Authors List of This Report Table 230. Secondary Sources Table 231. Primary Sources List of Figures Figure 1. Varicella Virus Attenuated Live Vaccine Image Figure 2. Global Varicella Virus Attenuated Live Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Varicella Virus Attenuated Live Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 4. Child Image Figure 5. Adult Image Figure 6. Global Varicella Virus Attenuated Live Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Varicella Virus Attenuated Live Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 8. Government Institution Image Figure 9. Private Sector Image Figure 10. Other Image Figure 11. Global Varicella Virus Attenuated Live Vaccine Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global Varicella Virus Attenuated Live Vaccine Revenue (2021-2032) & (US$ Million) Figure 13. Global Varicella Virus Attenuated Live Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 14. Global Varicella Virus Attenuated Live Vaccine Revenue Market Share by Region: 2025 Versus 2032 Figure 15. Global Varicella Virus Attenuated Live Vaccine Revenue Market Share by Region (2021-2032) Figure 16. Global Varicella Virus Attenuated Live Vaccine Sales (2021-2032) & (k units) Figure 17. Global Varicella Virus Attenuated Live Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 18. Global Varicella Virus Attenuated Live Vaccine Sales Market Share by Region (2021-2032) Figure 19. US & Canada & Mexico Varicella Virus Attenuated Live Vaccine Sales YoY (2021-2032) & (k units) Figure 20. Europe Varicella Virus Attenuated Live Vaccine Sales YoY (2021-2032) & (k units) Figure 21. China Varicella Virus Attenuated Live Vaccine Sales YoY (2021-2032) & (k units) Figure 22. Asia (Excluding China) Varicella Virus Attenuated Live Vaccine Sales YoY (2021-2032) & (k units) Figure 23. South America, Middle East and Africa Varicella Virus Attenuated Live Vaccine Sales YoY (2021-2032) & (k units) Figure 24. Global Varicella Virus Attenuated Live Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 25. Global Varicella Virus Attenuated Live Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 26. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 27. Global Varicella Virus Attenuated Live Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 28. Global Varicella Virus Attenuated Live Vaccine Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 29. Global Varicella Virus Attenuated Live Vaccine Revenue Market Share by Type (2021-2032) Figure 30. Global Varicella Virus Attenuated Live Vaccine Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 31. Global Varicella Virus Attenuated Live Vaccine Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 32. Global Varicella Virus Attenuated Live Vaccine Sales Market Share by Type (2021-2032) Figure 33. Global Varicella Virus Attenuated Live Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 34. Global Varicella Virus Attenuated Live Vaccine Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 35. Global Varicella Virus Attenuated Live Vaccine Revenue Market Share by Application (2021-2032) Figure 36. Global Varicella Virus Attenuated Live Vaccine Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 37. Global Varicella Virus Attenuated Live Vaccine Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 38. Global Varicella Virus Attenuated Live Vaccine Sales Market Share by Application (2021-2032) Figure 39. North America Varicella Virus Attenuated Live Vaccine Revenue Share by Type (2021-2032) Figure 40. North America Varicella Virus Attenuated Live Vaccine Sales Share by Type (2021-2032) Figure 41. North America Varicella Virus Attenuated Live Vaccine Revenue Share by Application (2021-2032) Figure 42. North America Varicella Virus Attenuated Live Vaccine Sales Share by Application (2021-2032) Figure 43. North America Varicella Virus Attenuated Live Vaccine Revenue Share by Country (2021-2032) Figure 44. North America Varicella Virus Attenuated Live Vaccine Sales Share by Country (2021-2032) Figure 45. Europe Varicella Virus Attenuated Live Vaccine Revenue Share by Type (2021-2032) Figure 46. Europe Varicella Virus Attenuated Live Vaccine Sales Share by Type (2021-2032) Figure 47. Europe Varicella Virus Attenuated Live Vaccine Revenue Share by Application (2021-2032) Figure 48. Europe Varicella Virus Attenuated Live Vaccine Sales Share by Application (2021-2032) Figure 49. Europe Varicella Virus Attenuated Live Vaccine Revenue Share by Country (2021-2032) Figure 50. Europe Varicella Virus Attenuated Live Vaccine Sales Share by Country (2021-2032) Figure 51. China Varicella Virus Attenuated Live Vaccine Revenue Share by Type (2021-2032) Figure 52. China Varicella Virus Attenuated Live Vaccine Sales Share by Type (2021-2032) Figure 53. China Varicella Virus Attenuated Live Vaccine Revenue Share by Application (2021-2032) Figure 54. China Varicella Virus Attenuated Live Vaccine Sales Share by Application (2021-2032) Figure 55. Asia Varicella Virus Attenuated Live Vaccine Revenue Share by Type (2021-2032) Figure 56. Asia Varicella Virus Attenuated Live Vaccine Sales Share by Type (2021-2032) Figure 57. Asia Varicella Virus Attenuated Live Vaccine Revenue Share by Application (2021-2032) Figure 58. Asia Varicella Virus Attenuated Live Vaccine Sales Share by Application (2021-2032) Figure 59. Asia Varicella Virus Attenuated Live Vaccine Revenue Share by Country (2021-2032) Figure 60. Asia Varicella Virus Attenuated Live Vaccine Sales Share by Country (2021-2032) Figure 61. SAMEA Varicella Virus Attenuated Live Vaccine Revenue Share by Type (2021-2032) Figure 62. SAMEA Varicella Virus Attenuated Live Vaccine Sales Share by Type (2021-2032) Figure 63. SAMEA Varicella Virus Attenuated Live Vaccine Revenue Share by Application (2021-2032) Figure 64. SAMEA Varicella Virus Attenuated Live Vaccine Sales Share by Application (2021-2032) Figure 65. SAMEA Varicella Virus Attenuated Live Vaccine Revenue Share by Country (2021-2032) Figure 66. SAMEA Varicella Virus Attenuated Live Vaccine Sales Share by Country (2021-2032) Figure 67. Varicella Virus Attenuated Live Vaccine Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Varicella Virus Attenuated Live Vaccine Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Child
  • Adult
Applications
  • Government Institution
  • Private Sector
  • Other
Companies covered
  • GSK
  • Changsheng
  • Sanofi
  • Merck
  • Biken
  • Shanghai Institute
  • Keygen
  • Green Cross
  • BCHT

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Varicella Virus Attenuated Live Vaccine Market by Type
  3. 1.2.1 Global Varicella Virus Attenuated Live Vaccine Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Child
  5. 1.2.3 Adult
  6. 1.3 Varicella Virus Attenuated Live Vaccine Market by Application
  7. 1.3.1 Global Varicella Virus Attenuated Live Vaccine Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Government Institution
  9. 1.3.3 Private Sector
  10. 1.3.4 Other
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Varicella Virus Attenuated Live Vaccine Market Dynamics
  1. 2.1 Varicella Virus Attenuated Live Vaccine Industry Trends
  2. 2.2 Varicella Virus Attenuated Live Vaccine Industry Drivers
  3. 2.3 Varicella Virus Attenuated Live Vaccine Industry Opportunities and Challenges
  4. 2.4 Varicella Virus Attenuated Live Vaccine Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Varicella Virus Attenuated Live Vaccine Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Varicella Virus Attenuated Live Vaccine Revenue by Region
  3. 3.2.1 Global Varicella Virus Attenuated Live Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Varicella Virus Attenuated Live Vaccine Revenue by Region (2021-2026)
  5. 3.2.3 Global Varicella Virus Attenuated Live Vaccine Revenue by Region (2027-2032)
  6. 3.2.4 Global Varicella Virus Attenuated Live Vaccine Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Varicella Virus Attenuated Live Vaccine Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Varicella Virus Attenuated Live Vaccine Sales by Region
  9. 3.4.1 Global Varicella Virus Attenuated Live Vaccine Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Varicella Virus Attenuated Live Vaccine Sales by Region (2021-2026)
  11. 3.4.3 Global Varicella Virus Attenuated Live Vaccine Sales by Region (2027-2032)
  12. 3.4.4 Global Varicella Virus Attenuated Live Vaccine Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Varicella Virus Attenuated Live Vaccine Revenue by Manufacturers
  2. 4.1.1 Global Varicella Virus Attenuated Live Vaccine Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Varicella Virus Attenuated Live Vaccine Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Varicella Virus Attenuated Live Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Varicella Virus Attenuated Live Vaccine Sales by Manufacturers
  6. 4.2.1 Global Varicella Virus Attenuated Live Vaccine Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Varicella Virus Attenuated Live Vaccine Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Varicella Virus Attenuated Live Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Varicella Virus Attenuated Live Vaccine Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Varicella Virus Attenuated Live Vaccine Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Varicella Virus Attenuated Live Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Varicella Virus Attenuated Live Vaccine Manufacturers, Product Type & Application
  13. 4.7 Global Varicella Virus Attenuated Live Vaccine Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Varicella Virus Attenuated Live Vaccine Market CR5 and HHI
  16. 4.8.2 2025 Varicella Virus Attenuated Live Vaccine Tier 1, Tier 2, and Tier 3
5 Varicella Virus Attenuated Live Vaccine Market by Type
  1. 5.1 Global Varicella Virus Attenuated Live Vaccine Revenue by Type
  2. 5.1.1 Global Varicella Virus Attenuated Live Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Varicella Virus Attenuated Live Vaccine Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Varicella Virus Attenuated Live Vaccine Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Varicella Virus Attenuated Live Vaccine Sales by Type
  6. 5.2.1 Global Varicella Virus Attenuated Live Vaccine Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Varicella Virus Attenuated Live Vaccine Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global Varicella Virus Attenuated Live Vaccine Sales Market Share by Type (2021-2032)
  9. 5.3 Global Varicella Virus Attenuated Live Vaccine Price by Type
6 Varicella Virus Attenuated Live Vaccine Market by Application
  1. 6.1 Global Varicella Virus Attenuated Live Vaccine Revenue by Application
  2. 6.1.1 Global Varicella Virus Attenuated Live Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Varicella Virus Attenuated Live Vaccine Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Varicella Virus Attenuated Live Vaccine Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Varicella Virus Attenuated Live Vaccine Sales by Application
  6. 6.2.1 Global Varicella Virus Attenuated Live Vaccine Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Varicella Virus Attenuated Live Vaccine Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global Varicella Virus Attenuated Live Vaccine Sales Market Share by Application (2021-2032)
  9. 6.3 Global Varicella Virus Attenuated Live Vaccine Price by Application
7 Company Profiles
  1. 7.1 GSK
  2. 7.1.1 GSK Company Information
  3. 7.1.2 GSK Business Overview
  4. 7.1.3 GSK Varicella Virus Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 GSK Varicella Virus Attenuated Live Vaccine Product Portfolio
  6. 7.1.5 GSK Recent Developments
  7. 7.2 Changsheng
  8. 7.2.1 Changsheng Company Information
  9. 7.2.2 Changsheng Business Overview
  10. 7.2.3 Changsheng Varicella Virus Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Changsheng Varicella Virus Attenuated Live Vaccine Product Portfolio
  12. 7.2.5 Changsheng Recent Developments
  13. 7.3 Sanofi
  14. 7.3.1 Sanofi Company Information
  15. 7.3.2 Sanofi Business Overview
  16. 7.3.3 Sanofi Varicella Virus Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Sanofi Varicella Virus Attenuated Live Vaccine Product Portfolio
  18. 7.3.5 Sanofi Recent Developments
  19. 7.4 Merck
  20. 7.4.1 Merck Company Information
  21. 7.4.2 Merck Business Overview
  22. 7.4.3 Merck Varicella Virus Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Merck Varicella Virus Attenuated Live Vaccine Product Portfolio
  24. 7.4.5 Merck Recent Developments
  25. 7.5 Biken
  26. 7.5.1 Biken Company Information
  27. 7.5.2 Biken Business Overview
  28. 7.5.3 Biken Varicella Virus Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 Biken Varicella Virus Attenuated Live Vaccine Product Portfolio
  30. 7.5.5 Biken Recent Developments
  31. 7.6 Shanghai Institute
  32. 7.6.1 Shanghai Institute Company Information
  33. 7.6.2 Shanghai Institute Business Overview
  34. 7.6.3 Shanghai Institute Varicella Virus Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Shanghai Institute Varicella Virus Attenuated Live Vaccine Product Portfolio
  36. 7.6.5 Shanghai Institute Recent Developments
  37. 7.7 Keygen
  38. 7.7.1 Keygen Company Information
  39. 7.7.2 Keygen Business Overview
  40. 7.7.3 Keygen Varicella Virus Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 Keygen Varicella Virus Attenuated Live Vaccine Product Portfolio
  42. 7.7.5 Keygen Recent Developments
  43. 7.8 Green Cross
  44. 7.8.1 Green Cross Company Information
  45. 7.8.2 Green Cross Business Overview
  46. 7.8.3 Green Cross Varicella Virus Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Green Cross Varicella Virus Attenuated Live Vaccine Product Portfolio
  48. 7.8.5 Green Cross Recent Developments
  49. 7.9 BCHT
  50. 7.9.1 BCHT Company Information
  51. 7.9.2 BCHT Business Overview
  52. 7.9.3 BCHT Varicella Virus Attenuated Live Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 BCHT Varicella Virus Attenuated Live Vaccine Product Portfolio
  54. 7.9.5 BCHT Recent Developments
8 North America
  1. 8.1 North America Varicella Virus Attenuated Live Vaccine Market Size by Type
  2. 8.1.1 North America Varicella Virus Attenuated Live Vaccine Revenue by Type (2021-2032)
  3. 8.1.2 North America Varicella Virus Attenuated Live Vaccine Sales by Type (2021-2032)
  4. 8.1.3 North America Varicella Virus Attenuated Live Vaccine Price by Type (2021-2032)
  5. 8.2 North America Varicella Virus Attenuated Live Vaccine Market Size by Application
  6. 8.2.1 North America Varicella Virus Attenuated Live Vaccine Revenue by Application (2021-2032)
  7. 8.2.2 North America Varicella Virus Attenuated Live Vaccine Sales by Application (2021-2032)
  8. 8.2.3 North America Varicella Virus Attenuated Live Vaccine Price by Application (2021-2032)
  9. 8.3 North America Varicella Virus Attenuated Live Vaccine Market Size by Country
  10. 8.3.1 North America Varicella Virus Attenuated Live Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Varicella Virus Attenuated Live Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Varicella Virus Attenuated Live Vaccine Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Varicella Virus Attenuated Live Vaccine Market Size by Type
  2. 9.1.1 Europe Varicella Virus Attenuated Live Vaccine Revenue by Type (2021-2032)
  3. 9.1.2 Europe Varicella Virus Attenuated Live Vaccine Sales by Type (2021-2032)
  4. 9.1.3 Europe Varicella Virus Attenuated Live Vaccine Price by Type (2021-2032)
  5. 9.2 Europe Varicella Virus Attenuated Live Vaccine Market Size by Application
  6. 9.2.1 Europe Varicella Virus Attenuated Live Vaccine Revenue by Application (2021-2032)
  7. 9.2.2 Europe Varicella Virus Attenuated Live Vaccine Sales by Application (2021-2032)
  8. 9.2.3 Europe Varicella Virus Attenuated Live Vaccine Price by Application (2021-2032)
  9. 9.3 Europe Varicella Virus Attenuated Live Vaccine Market Size by Country
  10. 9.3.1 Europe Varicella Virus Attenuated Live Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Varicella Virus Attenuated Live Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Varicella Virus Attenuated Live Vaccine Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Varicella Virus Attenuated Live Vaccine Market Size by Type
  2. 10.1.1 China Varicella Virus Attenuated Live Vaccine Revenue by Type (2021-2032)
  3. 10.1.2 China Varicella Virus Attenuated Live Vaccine Sales by Type (2021-2032)
  4. 10.1.3 China Varicella Virus Attenuated Live Vaccine Price by Type (2021-2032)
  5. 10.2 China Varicella Virus Attenuated Live Vaccine Market Size by Application
  6. 10.2.1 China Varicella Virus Attenuated Live Vaccine Revenue by Application (2021-2032)
  7. 10.2.2 China Varicella Virus Attenuated Live Vaccine Sales by Application (2021-2032)
  8. 10.2.3 China Varicella Virus Attenuated Live Vaccine Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Varicella Virus Attenuated Live Vaccine Market Size by Type
  2. 11.1.1 Asia Varicella Virus Attenuated Live Vaccine Revenue by Type (2021-2032)
  3. 11.1.2 Asia Varicella Virus Attenuated Live Vaccine Sales by Type (2021-2032)
  4. 11.1.3 Asia Varicella Virus Attenuated Live Vaccine Price by Type (2021-2032)
  5. 11.2 Asia Varicella Virus Attenuated Live Vaccine Market Size by Application
  6. 11.2.1 Asia Varicella Virus Attenuated Live Vaccine Revenue by Application (2021-2032)
  7. 11.2.2 Asia Varicella Virus Attenuated Live Vaccine Sales by Application (2021-2032)
  8. 11.2.3 Asia Varicella Virus Attenuated Live Vaccine Price by Application (2021-2032)
  9. 11.3 Asia Varicella Virus Attenuated Live Vaccine Market Size by Country
  10. 11.3.1 Asia Varicella Virus Attenuated Live Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Varicella Virus Attenuated Live Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Varicella Virus Attenuated Live Vaccine Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Varicella Virus Attenuated Live Vaccine Market Size by Type
  2. 12.1.1 SAMEA Varicella Virus Attenuated Live Vaccine Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Varicella Virus Attenuated Live Vaccine Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Varicella Virus Attenuated Live Vaccine Price by Type (2021-2032)
  5. 12.2 SAMEA Varicella Virus Attenuated Live Vaccine Market Size by Application
  6. 12.2.1 SAMEA Varicella Virus Attenuated Live Vaccine Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Varicella Virus Attenuated Live Vaccine Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Varicella Virus Attenuated Live Vaccine Price by Application (2021-2032)
  9. 12.3 SAMEA Varicella Virus Attenuated Live Vaccine Market Size by Country
  10. 12.3.1 SAMEA Varicella Virus Attenuated Live Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Varicella Virus Attenuated Live Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Varicella Virus Attenuated Live Vaccine Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Varicella Virus Attenuated Live Vaccine Value Chain Analysis
  2. 13.1.1 Varicella Virus Attenuated Live Vaccine Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Varicella Virus Attenuated Live Vaccine Production Mode & Process
  6. 13.2 Varicella Virus Attenuated Live Vaccine Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Varicella Virus Attenuated Live Vaccine Distributors
  9. 13.2.3 Varicella Virus Attenuated Live Vaccine Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst